Article: Nicotinamide Riboside Improves Alzheimer's Features and DNA Repair: Preclinical Findings

PrevNext
Muscle Health Orphan Disease Preclinical

Nicotinamide Riboside Improves Alzheimer's Features and DNA Repair: Preclinical Findings

Synopsis

Alzheimer’s disease (AD) involves problems with energy metabolism and DNA repair, but how these contribute to key AD features is unclear. A DNA repair-deficient AD mouse model (3xTgAD/Polβ+/−) shows worsened Tau protein pathology, synaptic problems, neuron death, and cognitive decline. These mice have a lower brain NAD+/NADH ratio, indicating impaired energy metabolism, which is restored by nicotinamide riboside (NR) treatment. NR reduced Tau pathology, DNA damage, neuroinflammation, and neuron death, while increasing brain SIRT3 activity. It also improved cognition and synaptic plasticity in both AD models, especially the repair-deficient one. These results highlight that NAD+ depletion contributes to AD pathology and that boosting NAD+ in neurons could be a promising therapeutic strategy.

Journal

Proceedings of the National Academy of Sciences

Share

Read more

COVID/Long-COVID

NAD+ Biosynthesis Enzyme Protects Aortic Smooth Muscle Cells: Preclinical Findings

Synopsis The walls of the aorta weaken with age and stress, risking serious damage. Smooth muscle cells (SMCs) in the aorta need NAD+, made by the enzyme NAMPT, for health. In humans with aortic d...

Read more
Alzheimer's Disease

Nicotinamide Riboside Reduces Brain Inflammation and Cellular Aging in Alzheimer’s Disease: Preclinical Findings

Synopsis In Alzheimer’s disease, brain cells often show low NAD+ levels, high inflammation, and impaired cellular cleanup of damaged components. In mice with Alzheimer’s-like brain changes, five m...

Read more